title: Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia.
abstract: BACKGROUND
  Statins are the agents of choice in reducing elevated plasma low-density lipoprotein cholesterol (LDL-C).
  
  
  OBJECTIVE
  Cerivastatin 0.8 mg has greater long-term efficacy in reducing LDL-C than pravastatin 40 mg in primary hypercholesterolemia.
  
  
  METHODS
  In this double-blind, parallel-group, 52-week study, patients (n = 1,170) were randomized (4:1:1) to cerivastatin 0.8 mg, cerivastatin 0.4 mg, or placebo daily. After 8 weeks, placebo was switched to pravastatin 40 mg. Patients with insufficient LDL-C lowering after 24 weeks were allowed open-labeled resin therapy.
  
  
  RESULTS
  Cerivastatin 0.8 mg reduced LDL-C versus cerivastatin 0.4 mg (40.8 vs. 33.6%, p <0.0001) or pravastatin 40 mg (31.5%, p<0.0001), and brought 81.8% of all patients, and 54.1% of patients with atherosclerotic disease, to National Cholesterol Education Program (NCEP) goals. Cerivastatin 0.8 mg improved mean total C (-29.0%), triglycerides (-18.3%), and high-density lipoprotein cholesterol (HDL-C) (+9.7%) (all p < or = 0.013 vs. pravastatin 40 mg). Higher baseline triglycerides were associated with greater reductions in triglycerides and elevations in HDL-C with cerivastatin. Cerivastatin was well tolerated; the most commonly reported adverse events were arthralgia, headache, pharyngitis, and rhinitis. Symptomatic creatine kinase > 10x the upper limit of normal (ULN) occurred in 1, 1.5, and 0% of patients receiving cerivastatin 0.8 mg, cerivastatin 0.4 mg, and pravastatin 40 mg, respectively. Repeat hepatic transaminases >3 x ULN occurred in 0.3-0.5, 0.5, and 0% of patients, respectively.
  
  
  CONCLUSIONS
  In long-term use, cerivastatin 0.8 mg effectively and safely brings the majority of patients to NCEP goal.
authors.affiliation: Medpace, Cincinnati, Ohio 45212, USA. J.Isaacsohn@medpace.com
authors.forename: J
authors.initials: J
authors.lastname: Isaacsohn
authors.forename: W
authors.initials: W
authors.lastname: Insull
authors.forename: E
authors.initials: E
authors.lastname: Stein
authors.forename: P
authors.initials: P
authors.lastname: Kwiterovich
authors.forename: M A
authors.initials: MA
authors.lastname: Patrick
authors.forename: R
authors.initials: R
authors.lastname: Brazg
authors.forename: C A
authors.initials: CA
authors.lastname: Dujovne
authors.forename: M
authors.initials: M
authors.lastname: Shan
authors.forename: E
authors.initials: E
authors.lastname: Shugrue-Crowley
authors.forename: S
authors.initials: S
authors.lastname: Ripa
authors.forename: R
authors.initials: R
authors.lastname: Tota
mesh_terms: D000293:Adolescent; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; C086276:cerivastatin; D017035:Pravastatin